DURECT Corporation EBITDA 2011-2025 | DRRX

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA DURECT Corporation

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-36.9 M	-35 M	-34 M	-12.3 M	-18.9 M	-23.4 M	-1.8 M	-31.9 M	-20.2 M	-20.4 M	-20.6 M	17 M	-17.7 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
17 M	-36.9 M	-19.7 M

Quarterly EBITDA DURECT Corporation

2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-4.07 M	-	-	-6.25 M	-	-	-11 M	-	-2.02 M	-11.1 M	-10.3 M	-	-9.37 M	-8.66 M	-9.62 M	-	-8.61 M	14.5 M	-9.76 M	-	-1.49 M	-6.62 M	-6.63 M	-	-2.13 M	-6.39 M	-7.72 M	-	6.46 M	-9.14 M	-7.46 M	-	-7.98 M	-8.29 M	-7.22 M	-	-5.63 M	-4.68 M	-4.28 M	-	-6.13 M	-5.14 M	-3.45 M	-	-5.34 M	-4.64 M	-4.94 M	-	-4.12 M	-3.92 M	31 M	-	-4.28 M	-4.77 M	-6.11 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
31 M	-11.1 M	-4.55 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Drug manufacturers industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Alimera Sciences ALIM	6.82 M	-	-	$ 142 M	USA
Canopy Growth Corporation CGC	-95.6 M	$ 1.31	-6.43 %	$ 141 M	Canada
Aerie Pharmaceuticals AERI	-40 M	-	-	$ 754 M	USA
Cronos Group CRON	-176 M	$ 2.74	-0.36 %	$ 1.44 B	Canada
AcelRx Pharmaceuticals ACRX	-16.6 M	-	7.5 %	$ 6.35 M	USA
Adamis Pharmaceuticals Corporation ADMP	-23.6 M	-	0.86 %	$ 117 M	USA
Agile Therapeutics AGRX	-19.8 M	-	10.11 %	$ 58.2 M	USA
Catalent CTLT	-260 M	-	-	$ 11.5 B	USA
Aurora Cannabis ACB	-283 M	$ 4.57	-1.72 %	$ 86.3 M	Canada
Eagle Pharmaceuticals EGRX	81.6 M	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	306 M	-	-	$ 28.9 M	Irlanda
Evoke Pharma EVOK	-7.43 M	-	-	$ 36.6 M	USA
Calliditas Therapeutics AB (publ) CALT	-524 M	-	-0.1 %	$ 2.03 B	Schweden
HEXO Corp. HEXO	-85.5 M	-	2.45 %	$ 38.1 M	Canada
Emergent BioSolutions EBS	-601 M	$ 12.63	0.72 %	$ 647 M	USA
Athenex ATNX	-65.5 M	-	-23.39 %	$ 1.76 M	USA
Avadel Pharmaceuticals plc AVDL	-39.7 M	$ 21.58	0.19 %	$ 2.05 B	France
Evolus EOLS	-29.1 M	$ 6.85	0.59 %	$ 425 M	USA
Harrow Health HROW	1.49 M	$ 50.16	2.05 %	$ 1.64 B	USA
OrganiGram Holdings OGI	-91.8 M	$ 1.76	1.15 %	$ 402 M	Canada
China Pharma Holdings CPHI	-1.97 M	$ 1.31	-1.5 %	$ 22.9 M	China
Bausch Health Companies BHC	2.23 B	$ 7.18	-1.91 %	$ 2.62 B	Canada
Lannett Company LCI	-142 M	-	1.15 %	$ 7.11 M	USA
Neoleukin Therapeutics NLTX	-52.3 M	-	-	$ 193 M	Canada
Cumberland Pharmaceuticals CPIX	3.06 M	$ 4.2	-1.41 %	$ 59.1 M	USA
Organogenesis Holdings ORGO	12.3 M	$ 5.87	2.09 %	$ 773 M	USA
Pacira BioSciences PCRX	5.41 M	$ 26.02	1.09 %	$ 1.2 B	USA
PetIQ PETQ	81.6 M	-	1.64 %	$ 400 M	USA
Radius Health RDUS	-53.2 M	-	-	$ 1.42 B	USA
Recro Pharma REPH	4.65 M	-	-4.76 %	$ 65.3 M	USA
Jupiter Wellness JUPW	429 K	-	-	$ 33.6 M	USA
Perrigo Company plc PRGO	439 M	$ 13.75	0.51 %	$ 1.89 B	USA
ProPhase Labs PRPH	28.3 M	$ 0.62	-10.48 %	$ 9.82 M	USA
Relmada Therapeutics RLMD	-104 M	$ 4.6	2.45 %	$ 138 M	USA
Rockwell Medical RMTI	-5.23 M	$ 0.81	-0.81 %	$ 18.9 M	USA
Sundial Growers SNDL	-132 M	$ 1.77	-0.56 %	$ 3.37 M	Canada
OptiNose OPTN	-22.3 M	-	-	$ 1.08 B	USA
Assertio Holdings ASRT	-215 M	$ 0.66	-0.02 %	$ 46.9 M	USA
Solid Biosciences SLDB	-127 M	$ 5.9	-	$ 241 M	USA
PLx Pharma PLXP	-40.7 M	-	-27.8 %	$ 2.56 M	USA
Sonoma Pharmaceuticals SNOA	-3.57 M	$ 3.64	1.68 %	$ 4.52 M	USA
SCYNEXIS SCYX	73.2 M	$ 0.6	1.78 %	$ 28.7 M	USA
Tricida TCDA	-153 M	-	-	$ 3.25 M	USA
Tilray TLRY	-1.37 B	$ 10.15	-3.61 %	$ 6.27 B	Canada
Veru VERU	-36.6 M	$ 2.34	0.86 %	$ 316 M	USA
TherapeuticsMD TXMD	-7.6 M	$ 1.7	3.66 %	$ 17.7 M	USA
cbdMD YCBD	-2.86 M	$ 1.59	-4.22 %	$ 6.86 M	USA
Viatris VTRS	4.64 B	$ 12.24	1.83 %	$ 14.8 B	USA
Zynerba Pharmaceuticals ZYNE	-35 M	-	-	$ 55.5 M	USA